Viralytics [ASX: VLA] has completed dosage administration of the second of three groups of patients in its phase 1 trial of its oncolytic virus technology Cavatak in late-stage metastatic melanoma patients.

After dosing the two groups the company has concluded that there were no adverse effects related to the medication, and that the two tested doses were well tolerated.

The company has also received ethics approval from the Drug Safety Monitoring Committee [DSMC] to provide an escalated dose to the final group of patients.

The final participants will include a tenfold higher dose than the second group, and a hundredfold higher dose than the first group.

Viralytics also has a second trial underway in prostate cancer patients.